Document ID: chunk:federal_register_of_legislation:F2016L00262:reg:9:p1
Version: federal_register_of_legislation:F2016L00262
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 3897–7004

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting systemic lupus erythematosus or death from systemic lupus erythematosus with the circumstances of a person's relevant service:
(1)          being exposed to sunlight or ultraviolet light at a level sufficient to induce erythema at least 24 hours, but not more than 30 days, before the clinical onset of systemic lupus erythematosus;
(2)          inhaling respirable crystalline silica dust, at the time material containing crystalline silica was being:
(a)          produced;
(b)          excavated;
(c)          drilled, cut or ground; or
(d)          used in construction, manufacturing, cleaning or blasting,
         for a cumulative period of at least 2 000 hours before the clinical onset of systemic lupus erythematosus;
(3)          where smoking has not ceased before the clinical onset of systemic lupus erythematosus, smoking at least ten pack-years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical onset of systemic lupus erythematosus;
Note: pack-years of cigarettes, or the equivalent thereof in other tobacco products is defined in the Schedule 1 – Dictionary.
(4)          being treated with a drug from the specified list of drugs at the time of the clinical onset of systemic lupus erythematosus;
Note: specified list of drugs is defined in the Schedule 1 – Dictionary.
(5)          being treated with a drug which is associated in the individual with:
(a)          the development of the symptoms or signs of systemic lupus erythematosus during drug therapy;
(b)          the cessation of the symptoms or signs of systemic lupus erythematosus within weeks of discontinuing drug therapy;
(c)          an absence of clinical or laboratory evidence of systemic lupus erythematosus prior to beginning drug therapy; and
(d)          the development of serological markers which reduce in titre on discontinuing drug therapy; and
         where treatment with the drug continued for at least the three days before the clinical onset of systemic lupus erythematosus;
(6)          having hormone replacement therapy with an oestrogen for at least the two years before the clinical onset of systemic lupus erythematosus;
(7)           being exposed to sunlight or ultraviolet light at a level sufficient to induce erythema at least 24 hours, but not more than 30 days, before the clinical worsening of systemic lupus erythematosus;
(8)          inhaling respirable crystalline silica dust, at the time material containing crystalline silica was being:
(a)          produced;
(b)          excavated;
(c)          drilled, cut or ground; or
(d)          used in construction, manufacturing, cleaning or blasting,
         for a cumulative period of at least 2 000 hours before the clinical worsening of systemic lupus erythematosus;
(9)          where smoking has not ceased before the clinical onset of systemic lupus erythematosus, smoking at least ten pack-years of cigarettes,